Elanco Animal Health 株価情報 (NYSE: ELAN)

Elanco Animal Health (NYSE:ELAN) 株価情報

Elanco Animal Health

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health Inc

ELANIX BIOTECHNOLOGIES AG by ELANIX BIOTECHNOLOGIES AG

You've seen how AI is transforming trading desks, supply chains, and software stacks. Now it's creeping into a space that's historically run on gut instinct and Rolodexes: public relations.
And yes — there's an equity angle here.
Several publicly traded companies are leading the charge as communications technology evolves into an investable category:
<ul class="wp-block-list">
<li>Sprinklr (CXM) has repositioned itself from a pure customer experience play to a broader reputation management and media intelligence platform. Its tools now analyze brand sentiment across news and social media — attracting budget from PR and comms teams. </li>
<li>Salesforce (CRM) is baking communications forecasting into its Einstein AI engine, integrating PR campaign tracking and message testing into its Marketing Cloud ecosystem. </li>
<li>ZoomInfo (ZI), primarily used for B2B sales, is increasingly leveraged by PR teams for media list curation and journalist analytics, expanding its utility across go-to-market functions. </li>
</ul>
Meanwhile, Cision, the legacy PR software company once listed on the NYSE, has gone private under Platinum Equity but continues to roll up startups like Brandwatch and Factmata, doubling down on AI-driven media intelligence.
All this activity supports a broader market thesis: that communications tech is becoming a measurable, data-rich sector, and investors are waking up to it.
<h3 class="wp-block-heading">Industry Growth and Market Context</h3>
The global public relations market is <a href="https://www.thebusinessresearchcompany.com/report/public-relations-global-market-report">projected</a> to grow from $112.98 billion in 2025 to $143.19 billion by 2029, with a 6.1% CAGR. But the real acceleration is in the software stack. The PR tech market — valued at $10.57 billion in 2023 — is <a href="https://www.verifiedmarketresearch.com/product/media-intelligence-and-pr-software-market/">forecasted</a> to hit $27.51 billion by 2030, growing at 14.61% CAGR, according to recent research.
This surge is driven by a new category: predictive PR platforms — tools that use machine learning to forecast how media campaigns will perform, score the likelihood of journalist engagement, and spot reputation risk before it breaks.
<h3 class="wp-block-heading">The Rise of Predictive PR</h3>
AI is no longer just summarizing coverage after the fact. It's now helping teams simulate campaign outcomes, suggest optimal outreach windows, and match messaging with likely receptive reporters.
Leading the charge in this space are several high-growth, private platforms:
<ul class="wp-block-list">
<li>PRophet offers a proprietary "Earned Media Opportunity Score" to forecast the success of a media pitch before it's sent. </li>
<li>Signal AI is used by large enterprises and financial institutions to monitor shifting narratives and geopolitical risk in real time. </li>
<li>NewsWhip scans millions of articles and posts to detect rising trends and help PR teams act before stories go viral. </li>
<li>OnePitch uses AI to analyze pitch structure and recommend matched journalists — a favorite among lean startup teams and boutique agencies. </li>
</ul>
The appeal? Fewer blind pitches. Better media ROI. And measurable campaign intelligence in a world where narrative control is business-critical.
<h3 class="wp-block-heading">Why It Matters to The Market</h3>
If you&#8217;re trading biotech and a trial result gets buried, it affects flow. If a tech CEO goes viral for the wrong reasons, shorts pile in. If a retail brand gets blindsided by a TikTok controversy, Q4 earnings are on the line.
PR may be a soft power — but its impact is concrete. And now, with AI and analytics, it's becoming quantifiable.
This evolution mirrors what fintech, adtech, and martech have already gone through:
<ul class="wp-block-list">
<li>The shift from intuition to predictive intelligence </li>
<li>The movement from back-office to frontline strategy </li>
<li>The growing crossover from enterprise SaaS into investor portfolios </li>
</ul>
<h3 class="wp-block-heading">Final Word</h3>
Wall Street has Bloomberg. Advertising has The Trade Desk. PR is building its own version — and it's quietly becoming one of the most interesting plays in the AI SaaS stack.
If you&#8217;re looking for the next edge in data-driven influence, follow the money — and follow the narrative.

Opinion

General

AI Forecasting Comes to PR: Why It Matters To The Market

WIIM

Thermon Group Holdings shares are trading lower on possible continued weakness after the company issued FY26 guidance below estimates on Thursday morning.

<a href="https://truthsocial.com/@realDonaldTrump/114558783827880495">https://truthsocial.com/@realDonaldTrump/114558783827880495</a>

News

Trump: After Much Consideration And Negotiation, US Steel Will Remain In America; This Will Be A Planned Partnership Between United States Steel And Nippon Steel

<a href="https://www.bloomberg.com/news/articles/2025-05-23/salesforce-is-said-back-in-talks-to-acquire-informatica" title="https://www.bloomberg.com/news/articles/2025-05-23/salesforce-is-said-back-in-talks-to-acquire-informatica">https://www.bloomberg.com/news/articles/2025-05-23/salesforce-is-said-back-in-talks-to-acquire-informatica</a>

INFA

'Salesforce Is Back in Talks to Acquire Informatica' -Bloomberg

Wall Street economists breathed a sigh of relief last week when the <a href="https://www.newyorkfed.org/microeconomics/hhdc">Federal Reserve Bank of New York's report</a> on household debt in the first quarter disclosed a 2% drop in credit card balances, falling by $29 billion. These folks have grown cautious examining Americans' near-record-level revolving debt, $1,282 trillion in the first quarter, worried they lack the assets to pay their bills. This can signal economic stress that precedes a recession.&nbsp;
Total household debt still rose by $167 billion in the quarter, reaching $18.2 trillion. Housing, auto loans and student loans contributed to the total, highlighting major challenges in maintaining a healthy economy. Student loans pose the most troubling obstacle to prosperity right now, with President Donald Trump restarting payment requirements.&nbsp;
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Bankrate senior industry analyst Ted Rossman <a href="https://www.bankrate.com/credit-cards/news/credit-card-balances-fell-q1-2025-borrowers-still-underwater/">warned economists</a> to tread lightly after the report, noting that credit card balances "almost always fall in the first quarter, because people go on this post-holiday spending detox." He explained that borrowers often make New Year&#8217;s resolutions to "spend less, save more, pay off debt" and "use tax refund money to pay off debt." However, balances "almost always rise in the second and third quarters" and "really spike in the fourth quarter."
Credit card usage has skyrocketed since the pandemic, jumping 54% in the last four years. Fortunately, benign reasons may be responsible for at least part of the surge. A tech-savvy generation has popularized germfree electronic transactions since COVID, disrupting formerly cash-heavy venues like supermarkets, pharmacies and transportation. Even so, stressed-out Americans trying to make ends meet are playing a major role in the debt spike.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
According to Rossman, about half of Americans now pay off their credit card balances each month, avoiding interest rates that average above 20%. This crowd is less profitable for <a href="https://www.benzinga.com/quote/V">Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</a>, <a href="https://www.benzinga.com/quote/MA">Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>)</a> and other payment processors, accessing lucrative perks that include travel points and cashback programs. Those who don't pay their balances each month assume the burden, stuck with high interest rates to compensate for more affluent or disciplined customers.
Credit card borrowers under economic stress are climbing a very tall hill because the average balance is now approaching $6,000 per month. When they don't pay their balances, the ‘minimum payment' becomes a lucrative trap for card processors, taking an average 18 or more years for borrowers with a 20% interest rate to close out the debt. It will also incur nearly $10,000 in interest payments.&nbsp;
See Also: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
&nbsp;Borrowers are seeking help at increasingly alarming rates. Nonprofit credit counseling leader <a href="https://www.globenewswire.com/news-release/2025/01/17/3011652/0/en/Money-Management-International-Reports-Surge-in-Debt-Counseling-in-2024-Disproportionate-Increase-Among-Young-Adults.html">Money Management International</a> reported a 35% spike in new clients last year, fueled by young adults – especially <a href="https://www.globenewswire.com/news-release/2025/05/01/3072462/0/en/New-Data-from-Nonprofit-MMI-Reveals-Rise-in-Men-Seeking-Credit-Counseling-Despite-Higher-Incomes.html">single men</a> – facing the reality of loans under default. In addition to outside assistance, Rossman suggests looking for a 0% balance transfer card. These are special cards offered by large institutions that feature 0% or ultralow introductory rates for a specified period that can last up to two years.&nbsp;
Just make sure to pay off your balance before the clock runs out, or you'll find yourself underwater once again.
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a> </li>
</ul>
Image: Shutterstock

Personal Finance

Credit Card Debt Falls, but Bankrate's Ted Rossman Says It's No Time to Cheer

With more and more crypto <a href="https://www.benzinga.com/etfs">ETFs listed on U.S. exchanges</a>, investors are now faced with a paradox of choice. From spot and futures-based funds to leveraged and income-oriented strategies, the new ETF universe is not only crowded, its structurally complicated.
And those structures matter—not just for returns, but for volatility, fees, and taxes. In today's crowded ETF landscape, knowing what you own and how it works is as critical as timing your entry.
Beyond The Ticker: Why Structure Matters
All Bitcoin <a href="https://www.benzinga.com/crypto">ETFs provide exposure to crypto</a> without the hassles of exchanges and wallets. But stop there. That&#8217;s where the similarities end. Each type of Bitcoin ETF is constructed differently, directly impacting how it will perform in your portfolio.
Let&#8217;s examine how these differences work out.
Spot ETFs: The Simplest Option
Spot Bitcoin ETFs like iShares Bitcoin Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) provide direct Bitcoin exposure in a regulated format. Their appeal lies in simplicity: low turnover, tight price tracking, and minimal capital gains distributions—making them cost-efficient and ideal for long-term, buy-and-hold investors.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45592811/bitcoin-extends-rally-from-may-lows-can-it-break-120000-next">Bitcoin Extends Rally From May Lows — Can It Break $120,000 Next?</a>
Futures-Based ETFs: Exposure To Trading, Not The Asset
Futures-based Bitcoin ETFs like CoinShares Valkyrie Bitcoin and Ether Strategy ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTF#NASDAQ">BTF</a>) use derivatives, not actual Bitcoin, which can cause returns to diverge from spot prices—especially over time. In contango markets, rolling contracts reduce returns. These ETFs suit short-term directional bets, not passive holding. Investors must watch roll costs, expirations, and fund strategy closely.
Leveraged ETFs: Volatility With An Exclamation Point
Leveraged Bitcoin ETFs, such as Volatility Shares 2x Bitcoin Strategy ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BITX#BATS">BITX</a>), aim to double or triple Bitcoin's daily moves using futures, swaps, and frequent rebalancing. While they offer high short-term upside, compounding can erode returns over time—especially in volatile markets. These funds demand active management and aren&#8217;t suited for long-term holding.
Covered Call ETFs: Building Income, Limiting Upside
A newer category is income-focused Bitcoin ETFs, like Roundhill Bitcoin Covered Call Strategy ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/YBTC#BATS">YBTC</a>), which generate yield by selling options on crypto holdings. These strategies offer cash flow and perform best in sideways or mildly bullish markets, but they cap upside potential and often come with less favorable tax treatment.
Selecting By Use Case
Each Bitcoin ETF structure serves a distinct purpose:
<ul class="wp-block-list">
<li>Spot ETFs suit long-term holders wanting direct exposure with low complexity.</li>
<li>Futures-based ETFs cater to tactical traders chasing momentum—risk-aware and hands-on.</li>
<li>Leveraged ETFs are for aggressive, short-term bets—high risk, high maintenance.</li>
<li>Covered call ETFs offer income and dampened volatility, but cap upside potential.</li>
</ul>
What they all have in common is that they require transparency: the design determines how the ETF will perform, not only in terms of price, but in terms of suitability, risk, and yes, taxes.
One Fund, Many Outcomes
Two investors can both hold a "Bitcoin ETF" yet experience vastly different outcomes. One might enjoy low-cost, tax-efficient growth; the other could face weak returns or unexpected taxes.
The takeaway: with a growing array of crypto ETFs, due diligence is essential. Knowing the fund's name or fees isn't enough—you need to understand exactly what it holds and how it works.
Also Read: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45593231/trump-sparks-uranium-frenzy-nuclear-etfs-see-explosive-gains">Trump Sparks Uranium Frenzy: Nuclear ETFs See Explosive Gains</a></li>
</ul>
Photo: egaranugrah On Shutterstock.com

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Sector ETFs

ETFs

BITX

IBIT

YBTC

Not All Bitcoin ETFs Are Created Equal: Here's How Structure Shapes Risk, Returns, And Taxes

Clear Secure shares are trading lower. The company disclosed that its director sold $8.96 million worth of stock.

From Texas&#8217; escalating war on hemp to EU-certified inhalers and Argentina&#8217;s full-scale overhaul of its medical cannabis program, this week offered no shortage of headlines that could shape the future of the cannabis industry across borders and sectors.
Let&#8217;s dig in. 
<h3 class="wp-block-heading">Policy &amp; Legal</h3>
Texas House Passes Hemp Ban, Threatens 50,000 Jobs
In a late-night vote Wednesday, the Texas House passed SB 3, banning hemp-derived THC products across the state. Championed by Lt. Gov. Dan Patrick, the measure criminalizes products containing any THC or THCA, despite opposition from 50% of voters, per a Texas Politics Project poll. The state's hemp industry, supporting 53,000 jobs and $268 million in tax revenue, now braces for litigation. Advocates are urging a veto.
Meanwhile, HB 46, aimed at expanding Texas' Compassionate Use Program, remains pending in the Senate. It proposes adding qualifying conditions like chronic pain, expanding licensing, and permitting more administration methods—but retains the 1% THC cap and bans flower.
DEA Report Criticizes Legal States, Admits Prohibition Fuels Illicit Trade
In its 2025 National Drug Threat Assessment, the DEA accused cartels of exploiting state-legal cannabis programs. However, the report also acknowledged that demand for illicit cannabis is driven largely by prohibition states—ironically making the case for federal reform.
DEA nominee Terrance Cole, in confirmation hearings, refused to take a position on rescheduling cannabis but called review of the issue a "first priority."
Read more on <a href="https://www.marijuanamoment.net/dea-blames-legal-marijuana-states-for-inadvertently-aiding-cartels-while-also-admitting-that-prohibition-states-create-illegal-market-opportunities">Marijuana Moment</a>
Argentina Overhauls REPROCANN Framework
The Ministry of Health issued Resolution 1780/2025, revamping Argentina's cannabis cultivation registry. Key changes include new rules for nonprofit growers, research institutions, and third-party cultivators, plus mandatory training and digital registration for prescribing doctors. While patients can retain current registrations for up to 3 years, others face stricter 1-year renewals and enhanced oversight.
Full breakdown via <a href="https://elplanteo.com/reprocann-cambios-2025">El Planteo</a>
<h3 class="wp-block-heading">Corporate &amp; M&amp;A</h3>
Blüm Holdings to Deepen Stake in Cookies
Blüm Holdings, Inc. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/BLMH#OTCQB">BLMH</a>) signed a binding term sheet to acquire 100% of a holding company with an indirect equity stake in Cookies Creative Consulting &amp; Promotions, Inc. The transaction—worth roughly $562,500—could amplify Blüm's presence alongside one of cannabis's most recognized brands.
Village Farms Spins Off Fresh Produce Arm to Focus on Cannabis
Village Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) will transfer key greenhouse and distribution assets to a new private joint venture with Sweat Equities, dubbed Vanguard Food LP. The move unlocks $40 million in cash and refocuses the company's strategy on international cannabis.
<h3 class="wp-block-heading">Global Markets</h3>
Canada: Industry Pushes for Excise Tax Reform
Deloitte's 2025 report confirmed that Canada's cannabis excise tax model is crushing legal operators. The Cannabis Council of Canada renewed calls to replace the $1/gram floor with a 10% ad valorem tax, noting that current rules are outdated and misaligned with market prices.
GrowerIQ to Represent Canada on Thailand Trade Mission
Toronto-based GrowerIQ was selected by Global Affairs Canada to join a trade mission to Thailand, becoming the only cannabis company in the delegation. Thailand's market, legal since 2022, is expected to grow at a 33% CAGR over five years.
Tilray Launches &#8216;Good Supply&#8217; in Germany
Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) expanded its European medical cannabis footprint with Good Supply's launch in Germany. Strains include Snow Leopard, Purple Octane and Lemon Haze Gelato. Products will be available via prescription at German pharmacies.
Read more on <a href="https://www.benzinga.com/markets/cannabis/25/05/45573520/after-bankruptcy-and-a-lost-home-this-cannabis-team-rebuilt-from-the-ground-up-the-real-story-of-blimburn-seeds">Benzinga</a>
Curaleaf and TILT Secure EU Certification for Medical Inhaler
Curaleaf International, a subsidiary of Curaleaf (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) and TILT Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TLLTF#OTC">TLLTF</a>) announced EU Class IIa certification for their new handheld medical cannabis inhaler. The approval unlocks opportunities across the EU, UK, Canada, and Australasia.
<h3 class="wp-block-heading">Financials</h3>
Planet 13 Reports Q1 Revenue of $28M
Planet 13 Holdings (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/PLNH#OTCQX">PLNH</a>) posted $28 million in Q1 2025 revenue—a 22.5% YoY increase. Gross margins shrank to 42.8%, while adjusted EBITDA swung to a $2.5 million loss. The company cited pressure on pricing and consumer demand.
Vext Grows Revenue 38%, Hits $3.1M in Operating Cash Flow
Vext Science (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/VEXTF#OTCQX">VEXTF</a>) reported $11.6 million in Q1 revenue, up 38% YoY. Operating cash flow reached $3.1 million. The company highlighted growth in Ohio and retail resilience in Arizona.
<h3 class="wp-block-heading">Events &amp; Culture</h3>
#InvestInHER Returns to Benzinga Cannabis Capital Conference
Women-led groups like Women Grow, Verdant Strategies and IWC will host mentorship and networking events during the Benzinga Cannabis Capital Conference in Chicago (June 8–10). The #InvestInHER Lounge and scholarship programs aim to boost visibility, funding access, and leadership for women founders.
More info <a href="http://bzcannabis.com">here</a>
<h3 class="wp-block-heading">Recommended Reads Of The Week</h3>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/events/25/05/45526151/modelo-got-it-right-cannabis-didnt-says-latina-ceo-who-built-a-multi-state-business-with-10k">Modelo Got It Right, Cannabis Didn&#8217;t, Says Latina CEO Who Built A Multi-State Business With $10K</a></li>
<li><a href="https://www.forbes.com/sites/javierhasse/2025/05/19/how-cannabis-drinks-are-reshaping-booze/">Weed In A Can: How Cannabis Drinks Are Changing The Ritual Of Drinking</a></li>
<li><a href="https://www.forbes.com/sites/javierhasse/2025/05/21/is-cannabis-justice-good-business-ben--jerrys-thinks-so/">Is Cannabis Justice Good Business? Ben &amp; Jerry's Thinks So</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/25/05/45573520/after-bankruptcy-and-a-lost-home-this-cannabis-team-rebuilt-from-the-ground-up-the-real-story-of-blimburn-seeds">After Bankruptcy And A Lost Home, This Cannabis Team Rebuilt From The Ground Up</a></li>
<li><a href="https://www.greenstate.com/lifestyle/premium-pot-products-newbie/">I gave a weed newbie some premium pot products—here's what he thought</a></li>
</ul>

Cannabis

Government

Politics

BLMH

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

PLNH

TLLTF

TLRY

VEXTF

This Week In Cannabis: DEA Slams Legal Weed, Texas Votes Hemp Ban, Argentina Tightens Medical Rules And More

Frontline shares are trading higher after the company reported a Q1 revenue beat.

Salesforce shares are trading lower after Citigroup cut its price target on the stock from $335 to $320 and maintained a Neutral rating.

JP Morgan analyst Samik Chatterjee shared earnings previews for several prominent hardware companies, cautioning that these firms may contend with ongoing demand uncertainty and renewed tariff risks in their <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings" rel="noreferrer noopener">upcoming earnings reports</a>.
Chatterjee sees another round of conservative results in the coming week, with stock movements more likely to reflect how investors interpret management&#8217;s efforts to either de-risk the second half of the year or contain expectations for potential full-year downside, especially after stronger-than-expected performances in the first half.
In contrast to HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) and Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>), the analyst sees Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) and NetApp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) as better situated to withstand anticipated headwinds in their upcoming earnings.
Also Read:<a href="https://www.benzinga.com/news/large-cap/25/05/45538647/accenture-dell-nvidia-deliver-on-premise-ai-solution-for-regulated-industries" target="_blank" rel="noreferrer noopener"> Accenture, Dell, NVIDIA Deliver On-Premise AI Solution For Regulated Industries</a>
The analyst anticipates that DELL&#8217;s demand drivers, particularly from less macro-sensitive AI spending and its stronger-than-expected AI market share, will effectively offset broader macroeconomic moderation as they look beyond the immediate quarterly results. 
Conversely, the analyst expects HPQ and HPE to be more sensitive to macro trends throughout the year. The analyst also notes that while NTAP shows greater resilience, its revenue upside is limited, as it relies on market share gains to counteract any macro weakness.
Here are the analyst&#8217;s take on some key hardware stocks:
Dell Technologies Inc.: The analyst reiterated the Overweight rating on the stock, raising the price <a href="https://www.benzinga.com/quote/DELL/analyst-ratings" target="_blank" rel="noreferrer noopener">forecast from $108 to $111</a>.
Chatterjee projects the upcoming first-quarter report to look solid on the surface, with strong PC and server demand boosting revenue and margins benefiting from a lower-than-expected mix of AI server sales. However, the analyst cautions that the tariff landscape remains a key concern.
Chatterjee writes that this issue will likely be reflected in second-quarter guidance and possibly in the fiscal 2026 outlook, as the company&#8217;s current baseline assumes higher tariff levels than previously expected, even with reciprocal tariff pauses in place.
The analyst projects revenue of $23.6 billion, reflecting a 6% year-over-year increase. He also predicts gross margins to come in at 22.5%, with operating margins forecasted at 7.9%, pointing to modest strength in profitability metrics.
Hewlett Packard Enterprise Company: Chatterjee sees the stock as the most favorably positioned among hardware <a href="https://www.benzinga.com/quote/HPE/analyst-ratings" target="_blank" rel="noreferrer noopener">names going into earnings, at least on a near-term basis</a>.
The analyst notes that the company&#8217;s guidance already factors in a slowdown in AI server revenue and assumes a higher tariff burden than peers.
Additionally, he highlights potential upside from stronger networking demand, supported by recent positive results from companies like Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), Extreme Networks, Inc., and Juniper Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>).
Chatterjee estimates revenue at $32.4 billion, reflecting 8% year-over-year growth. He forecasts gross margins at 28.7% and operating margins at 9.5%.
HP Inc.: Per the analyst, the company is in a strong position to post a solid second-quarter result, supported by stronger-than-expected revenue as PC demand was likely pulled <a target="_blank" href="https://www.benzinga.com/quote/HPQ/analyst-ratings" rel="noreferrer noopener">forward ahead of potential tariff-driven price hikes</a>.
Chatterjee notes that this comes with limited margin pressure, helped by delayed policy effects, inventory management, and other mitigating factors.
However, he cautions that macroeconomic uncertainty could limit how much of these near-term gains carry into future quarters, as the company faces two key challenges: navigating higher tariffs than previously guided for and uncertainty around PC demand in the second half of fiscal 2025 following earlier-than-usual buying.
The analyst reiterated the Overweight rating on the stock, raising the price forecast from $29 to $30.
NetApp, Inc.: The analyst expects NetApp to see stable demand, supported by new product launches and delayed deals from the previous quarter, leading to a slight revenue beat in F4Q25E. However, FY26 revenue growth is projected to be in the low-to-mid single digits, below long-term averages, due to a muted macro environment and U.S. Public Sector headwinds.
Despite this, EPS is anticipated to exceed consensus due to resilient gross margins (improved product margins and higher Public Cloud revenue mix) and better operating discipline. This positive outlook is expected to drive NTAP&#8217;s valuation multiple back to recent year averages (14x-15x) from the current 13x.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45572375/my-top-big-tech-option-trade-of-the-week" target="_blank" rel="noreferrer noopener">My Top Big Tech Option Trade Of The Week</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Equities

Price Target

Reiteration

Markets

Analyst Ratings

Tech

Trading Ideas

CSCO

DELL

JNPR

NTAP

Hewlett Packard, NetApp Better Positioned To Sidestep Tariff Headwinds Ahead of Earnings: Analyst

<a href="https://www.bloomberg.com/news/articles/2025-05-23/commscope-is-considering-sale-of-broadband-arm-ccs" title="https://www.bloomberg.com/news/articles/2025-05-23/commscope-is-considering-sale-of-broadband-arm-ccs">https://www.bloomberg.com/news/articles/2025-05-23/commscope-is-considering-sale-of-broadband-arm-ccs</a>

COMM

'CommScope Is Considering Sale Of Broadband Arm CCS '- Bloomberg

Shares of SharpLink Gaming Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) surged62.8% to $6.12 Friday afternoon, continuing a sharp upward trajectory despite no company-specific news released during the session. The stock has gained significant momentum following Tuesday's <a href="https://www.benzinga.com/pressreleases/25/05/g45517396/sharplink-gaming-announces-pricing-of-4-5-million-public-offering-priced-at-the-market-under-nasda">announcement</a> of a public offering.
What To Know: Trading volume spiked to over 4.2 million shares Friday afternoon, far exceeding its 100-day average of approximately 131,000, signaling heightened investor interest. 
SBET&#8217;s short interest remains notably high, with 71.55% of its float, equating to roughly 384,000 shares, held short. This sharp rally suggests a potential short squeeze may be driving part of the gains.
On Tuesday, SharpLink <a href="https://www.benzinga.com/pressreleases/25/05/g45517396/sharplink-gaming-announces-pricing-of-4-5-million-public-offering-priced-at-the-market-under-nasda">revealed</a> the pricing of a "reasonable best efforts" public offering of up to 1.53 million shares at $2.94 per share, aimed at raising $4.5 million in gross proceeds. 
Proceeds for the offering are earmarked for working capital and general corporate purposes.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45592743/stocks-bitcoin-fall-on-trumps-tariff-threats-gold-rallies-whats-driving-markets-friday">Stocks, Bitcoin Fall On Trump&#8217;s Tariff Threats, Gold Rallies: What&#8217;s Driving Markets Friday?</a>
<h2 class="wp-block-heading">How To Buy SBET Stock</h2>
By now you're likely curious about how to participate in the market for SharpLink Gaming &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of SharpLink Gaming, which is trading at $6.12 as of publishing time, $100 would buy you 16.34 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Photo: Shutterstock

SBET

SharpLink Gaming (SBET) Stock Soars 53%: What's Going On?

Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) saw several analysts reiterate their coverage, with one analyst making a modest reduction to the price forecast following <a target="_blank" href="https://www.benzinga.com/quote/wsm/analyst-ratings" rel="noreferrer noopener">Thursday&#8217;s first-quarter results</a>.
The retailer reported revenue of&nbsp;$1.73 billion, a&nbsp;4.2%&nbsp;increase from the same quarter last year and ahead of Wall Street&#8217;s estimate of&nbsp;$1.67 billion. GAAP earnings per share of&nbsp;$1.85&nbsp;beat the&nbsp;analyst <a target="_blank" href="https://www.benzinga.com//node/45569507" rel="noreferrer noopener">consensus estimate of&nbsp;$1.77</a>.
Williams-Sonoma maintains its fiscal 2025 and long-term&nbsp;outlook&nbsp;despite absorbing higher costs from the current tariff landscape. It emphasized that its&nbsp;guidance&nbsp;does not account for additional future tariffs and may be <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">revised if material changes occur</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45553623" rel="noreferrer noopener">Retail ETFs Rattle As Tariffs, Yields, Consumer Caution Pressure Big-Box Stocks</a>
Williams-Sonoma expects fiscal 2025 net revenue to range between&nbsp;-1.5%&nbsp;and&nbsp;+1.5%, with <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">comparable sales flat to up&nbsp;3.0%</a>.
RBC Capital Markets analyst Steven Shemesh lowered the price forecast to $182 from $189 while keeping an Outperform rating.
While first-quarter comps and headline operating margin outperformed expectations, investor concerns centered around the roughly 220 basis point headwind in merchandising gross margin, Shemesh noted.
Shemesh views much of this impact as temporary and expects improvement beginning in the second quarter. Consequently, the analyst revised the second quarter comp estimate to +1.2% (from -1.5%) and raised the adjusted EPS forecast to $1.81 from $1.74.
For 2025 and 2026, the analyst now projects comp sales growth of +1.1% and +2.6%, respectively (vs. +0.1% and +4.6% previously), and adjusted EPS of $8.33 and $9.10 (vs. $8.36 and $9.46 prior).
KeyBanc analyst Bradley B. Thomas reiterated an Overweight rating with a price forecast of $181.
The analyst says despite a challenging industry environment, the company delivered solid first-quarter results, with comparable sales and earnings per share surpassing expectations.
The analyst remains positive on Williams-Sonoma&#8217;s long-term outlook, driven by ongoing market share gains, a robust balance sheet, and sustainably elevated margins.
The analyst asserts that the company is well-positioned for an eventual housing recovery, with a potential over 50% upside in its shares within the next two to three years.
Thomas now estimates EPS of $1.71 (vs. $1.73 prior) for the second quarter, $1.87 (vs. $1.83 earlier) for the third quarter, and $3.02 (vs. $2.96 prior) for the fourth quarter of 2025.
Also, the analyst raised full-year 2025 EPS estimates to $8.44 (from $8.20) and 2026 EPS estimate to $8.75 (from $8.40).
Telsey Advisory analyst Cristina Fernández maintained an Outperform rating with a price forecast of $215.
The analyst views Williams-Sonoma&#8217;s quarterly performance as solid. However, year-over-year comparisons for gross and operating margins appear weaker due to a one-time adjustment in the first quarter of 2024.
Guggenheim Securities analyst Steven Forbes kept a Neutral rating and writes that while the company&#8217;s ~75 bps gross margin miss in the first quarter drew investor focus, the return to positive furniture comps (first since fourth-quarter 2022) is notable.
The analyst notes that all brands posted positive one-year comps for the first time since the second quarter of 2022, and multi-year comp trends improved across key banners. Forbes says this supports management&#8217;s outlook to return to top-line growth in 2025.
Having now accounted for the pressure from tariff-related margin headwinds, the analyst, by and large, is sticking to previous estimates.
Price Action: WSM shares are trading lower by 1.16% to $158.53&nbsp;at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45553623" target="_blank" rel="noreferrer noopener">Retail ETFs Rattle As Tariffs, Yields, Consumer Caution Pressure Big-Box Stocks</a></li>
</ul>
Photo via Shutterstock

Large Cap

Movers

Williams-Sonoma Poised For Over 50% Upside On Housing Rebound Hopes: Analyst

Cryptocurrency markets are trading lower amid heightened macroeconomic tensions, including a <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45585283/trump-tariff-threat-hits-europe-stocks-sink-as-50-duties-loom">fresh tariff threat</a> by president Donald Trump.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$108,866.35</td>
<td>-2.5%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,565.30</td>
<td>-3.7%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$179.62</td>
<td>+0.04%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.36</td>
<td>-2.91%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.2345</td>
<td>-3.2%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001477</td>
<td>-3.8%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows large transaction volume increasing by 26.2% and daily active addresses growing by 5.75%. Transactions greater than $100,000 are up from 14,030 to 16,506 in a single day. Exchanges netflows are down by 51.8%.</li>
<li>Coinglass data reports 161,179 traders were liquidated in the past 24 hours for $563.57 million.</li>
</ul>
Notable Developments:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45589084/solana-rallies-as-r3-partnership-signals-institutional-shift-sol-doge-bridge-introduced">Solana Rallies As R3 Partnership Signals Institutional Shift, SOL-DOGE Bridge Introduced</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45585060/pantera-ceo-predicts-surge-in-crypto-ipos-as-us-regulatory-tone-turns-favorable">Pantera CEO Predicts Surge In Crypto IPOs As US Regulatory Tone Turns Favorable</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45591475/congressman-bought-bitcoin-solana-xrp-in-december-and-didnt-hodl-a-look-at-missed-profits-by-selling-before-btc-all-time-highs">Congressman Bought Bitcoin, Solana, XRP In December — And Didn&#8217;t HODL: A Look At Missed Profits By Selling Before BTC All-Time Highs</a>v</li>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45579978/banking-giants-like-jpmorgan-bank-of-america-mull-joint-stablecoin-to-counter-crypto-competition-report">JPMorgan, Bank Of America, And Other Banking Titans Discussing Joint Stablecoin To Tackle Crypto Competition: Report</a></li>
<li><a href="https://www.benzinga.com/25/05/45588714/ripple-rebounds-stablecoin-launch-and-burn-strategy-add-tailwind">Ripple Rebounds; Stablecoin Launch And Burn Strategy Add Tailwind</a></li>
</ul>
Top Losers:
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>OFFICIAL TRUMP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>)</td>
<td>&nbsp;$13.31</td>
<td>-15.3%</td>
</tr>
<tr>
<td>Lido DAO (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">LDO</a>)</td>
<td>&nbsp;$0.9002</td>
<td>-8%</td>
</tr>
<tr>
<td>The Graph (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">GRT</a>)</td>
<td>&nbsp;$0.1141</td>
<td>-7.1%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Mayne sees Bitcoin's pullback as a dip into a key demand zone, likely triggered by market overreaction to Trump's EU trade rhetoric. 
If this level holds, it could set up a bullish weekend for BTC and altcoins.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> Pull back into demand here. Assuming this is an over reaction from Trump&#39;s talks with EU this is where we want to hold. Bullish weekend for BTC and Alts? <a href="https://t.co/GKUgruEEAR">pic.twitter.com/GKUgruEEAR</a>
&mdash; Mayne (@Tradermayne) <a href="https://twitter.com/Tradermayne/status/1925958786667212967?ref_src=twsrc%5Etfw">May 23, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
CryptoCon <a href="https://x.com/CryptoCon_/status/1925937107991707874">notes</a> this cycle is diverging from past bull runs, exchange balances are falling, not rising. That suggests retail hasn't arrived yet, and the mania phase is still to come.
Pentoshi <a href="https://x.com/Pentosh1/status/1925971068344283459">remains</a> long-term bullish, stating Bitcoin is on track to break all-time highs against gold and never look back. The ETF boom and institutional adoption are the catalysts.
Follis highlights Bitcoin's month-long ascending channel. As long as it holds, pullbacks near $106,000 are buying opportunities, with new highs on the table. Only a breakdown would warrant swing short setups.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> in an ascending channel for over a month Probably no swing shorts unless we break down Then you look for bearish retests Otherwise pullbacks to $106k area for buying, looking for new highs <a href="https://t.co/3H50aGb1hO">pic.twitter.com/3H50aGb1hO</a>
&mdash; フ ォ リ ス (@follis_) <a href="https://twitter.com/follis_/status/1925941516545019942?ref_src=twsrc%5Etfw">May 23, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45592811/bitcoin-extends-rally-from-may-lows-can-it-break-120000-next">Bitcoin Extends Rally From May Lows — Can It Break $120,000 Next?</a></li>
</ul>
Image: Shutterstock

$BTC

$DOGE

$ETH

Golden Ratio Token - United States Dollar

$GRT

$LDO

$SHIB

$SOL

$TRUMP

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Turn Red As Tariffs Threat Returns

Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab for <a href="https://www.benzinga.com/pressreleases/25/05/g45576972/merus-petosemtamab-with-pembrolizumab-interim-data-demonstrates-robust-efficacy-and-durability-in-">head and neck cancer.</a>
What To Know: The data, which will be formally presented at the 2025 ASCO Annual Meeting, showed a 63% overall response rate and a 79% 12-month overall survival rate among 43 evaluable patients with PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma.
The trial also reported a median progression-free survival of nine months, with six patients achieving complete responses and 21 showing partial responses. Importantly, no significant overlapping toxicities were observed in the treatment combination, which was generally well tolerated. Merus noted that 14 responders remained on therapy at the time of the Feb. 27 2025 data cutoff.
Analysts Weigh In: Needham raised its price target on Merus from $75 to $88, stating the updated data meaningfully de-risk the ongoing phase 3 trials. BMO Capital also raised its target from $96 to $110.
Topline data from one or both of the ongoing phase 3 studies are expected in 2026. 
MRUS Price Action: Merus shares were up 34.9% at $56.11 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45592743/stocks-bitcoin-fall-on-trumps-tariff-threats-gold-rallies-whats-driving-markets-friday">Stocks, Bitcoin Fall On Trump&#8217;s Tariff Threats, Gold Rallies: What&#8217;s Driving Markets Friday? </a></li>
</ul>
Image Via Shutterstock.

MRUS

Merus Stock Surges Over 35% On Strong Phase 2 Cancer Trial Results: What's Going On?

Wall Street analysts rerated Analog Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) after reporting <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45564073/analog-devices-cfo-confirms-cyclical-upturn-sees-continued-growth" rel="noreferrer noopener">fiscal second-quarter</a>&nbsp;results on Thursday.
The company&#8217;s quarterly revenue increased 22% to $2.64 billion, beating the analyst consensus estimate of $2.51 billion. Adjusted EPS of $1.85 beat the&nbsp;analyst consensus estimate&nbsp;of $1.70.
Analog Devices expects fiscal third-quarter 2025 revenue of $2.65 billion-$2.85 billion, above the&nbsp;analyst consensus estimate&nbsp;of $2.62 billion. The company projects adjusted EPS of $1.82-$2.02 against the analyst consensus estimate of $1.83.
<ul class="wp-block-list">
<li>Cantor Fitzgerald analyst Matthew Prisco reiterated a Neutral and a <a href="https://www.benzinga.com/quote/ADI/analyst-ratings" target="_blank" rel="noreferrer noopener">$250&nbsp;price target</a>.</li>
<li>Benchmark analyst David Williams maintained a Buy and lowered the price target from&nbsp;$275&nbsp;to&nbsp;$260.</li>
<li>Needham analyst Quinn Bolton reiterated with a Hold.</li>
<li>JP Morgan analyst Harlan Sur had an Overweight rating with a price target of $300.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/tech/25/05/45235394/nvidia-broadcom-lead-fund-manager-buys-even-as-semiconductor-sector-cools-analysts" target="_blank" rel="noreferrer noopener">Nvidia, Broadcom Lead Fund Manager Buys Even As Semiconductor Sector Cools: Analysts</a>
Cantor Fitzgerald: Similar to Analog peers, Analog Devices offered a solid beat and raise. Prisco noted a cyclical recovery in Industrials coupled with cyclical and idiosyncratic growth elsewhere.
Within Industrials, all sub-segments and geographies grew quarter over quarter. Factory Automation and the Broad-Based sub-segments also recovered.
Overall, book-to-bill was > 1.0, inventory downstream remains lean, and the company is bullish about the current cyclical upturn. Prisco noted some pull-ins that helped the April quarter, with no benefit likely in July. Industrials are still 10-15% below the trend line. A step up in operating expenditure related to variable compensation is weighing on the operating margin outlook into July. Still, there was a return to ~70% gross margins in the quarter.
Benchmark: Williams noted that Analog Devices&#8217; quarterly results and outlook were much better than the stock reaction suggested, with shares down over 4% on the day despite the healthy beat and raise. 
The analyst said the cyclical recovery continued gaining momentum, with bookings, backlog, and demand trends improving across all segments and geographies. Commentary around the automotive pull-ins spooked investors, although the company was obvious that order patterns have since normalized. 
Williams noted that the most encouraging takeaway from the report is the meaningful improvement from the industrial end market, where bookings and revenue grew across all subsegments. Industrial has been a mixed bag throughout the earnings season. 
Still, the results point to positive trends that should translate into better performance for the semi-group in the June quarter, per the analyst.&nbsp;&nbsp;
Needham: Bolton noted that Analog Devices reported results and guidance that easily exceeded Street&#8217;s expectations, which were driven by strength across most end markets. 
As per Bolton, auto grew +16% Q/Q, which came in much stronger than anticipated on tariff pull-ins in North America and Europe. He stated that Industrial increased +8% Q/Q in the quarter and is expected to grow another +10% Q/Q in the third quarter, driven by broad-based strength demonstrating early signs of a cyclical recovery. 
Bolton remarked that the operating margin will soon be under pressure due to higher variable compensation and increased salary expenses.
JPMorgan: Sur noted that Analog Devices delivered better quarterly results, driven by continued cyclical recovery trends and some customer demand pull-forward in their auto business.
However, the analyst noted that automotive revenue is expected to decline due to the headwind from the quarter&#8217;s demand pull forward. The industrial inventory correction is now complete, and the company will be shipping to end demand in the July quarter.&nbsp;&nbsp;
The team has multiple company-specific growth drivers, such as the AI-related markets, which can grow 20%- 25% Y/Y in fiscal 2025, and aerospace and defense strength, which is tracking to $1 billion in annualized revenues for the July quarter, Sur stated. 
Regarding tariffs, Analog Devices saw an acceleration in automotive sell-through and orders. Both the Americas and Europe automotive sectors are up 20% Q/Q following the announcement of the 25% auto tariff. However, the company saw no signs of demand pull-forward in other business segments.
Analog Devices is the first broad-based analog or microcontroller company to highlight customer demand pull-forward. Sur says this could likely weigh on second-half seasonal trends.
The first-half view is solid, though the analyst expected a weaker macro demand environment and sub-seasonal second-half trends.
Price Action:&nbsp;ADI stock is trading lower by 0.75% to $210.35 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/04/44770461/intel-on-slump-as-china-hits-us-made-chips-with-tariffs-amd-and-taiwan-semiconductor-rise-on-exemption-boost" target="_blank" rel="noreferrer noopener">China Hits US-Made Chips With Tariffs, But Those Outsourcing To Taiwan Semiconductor Exempt</a></li>
</ul>
Image: Shutterstock

Analog Devices Powers Past Estimates, But Shares Cool As Q2 Beat Masks Margin Pressure

Shares of ASP Isotopes Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) surged 14.4% to $8.92 Friday afternoon after the company announced a strategic financing <a href="https://ir.aspisotopes.com/sec-filings/all-sec-filings/content/0001477932-25-004124/0001477932-25-004124.pdf">agreement</a> with nuclear technology firm TerraPower and amid broader investor enthusiasm for nuclear energy stocks.
What To Know: On May 19, ASP Isotopes secured a loan commitment of up to $22 million from TerraPower to partially fund construction of a uranium enrichment facility in South Africa.
The plant, located at Pelindaba, will produce High Assay Low-Enriched Uranium, a critical fuel for next-generation reactors. ASP and TerraPower also inked supply agreements potentially worth over $4 billion through 2037.
The rally coincided with reports that President Donald Trump is <a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45593231/trump-sparks-uranium-frenzy-nuclear-etfs-see-explosive-gains">expected</a> to sign executive orders invoking the Defense Production Act to reduce U.S. dependence on foreign uranium and boost domestic nuclear development.
The dual catalysts, strategic financing and supportive U.S. policy, fueled gains across uranium stocks, with ASP Isotopes emerging as a standout Friday.
Read Also: <a href="https://www.benzinga.com/news/mid-cap/25/05/45587750/uranium-stocks-surge-trumps-nuclear-push-sparks-double-digit-gains">Uranium Stocks Surge: Trump&#8217;s Nuclear Push Sparks Double-Digit Gains</a>
<h2 class="wp-block-heading">How To Buy ASPI Stock</h2>
By now you're likely curious about how to participate in the market for ASP Isotopes &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of ASP Isotopes, which is trading at $8.92 as of publishing time, $100 would buy you 11.21 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ASPI has a 52-week high of $9.32 and a 52-week low of $1.86.
Image: Shutterstock

ASPI

ASP Isotopes (ASPI) Stock Rises On TerraPower Deal And US Nuclear Policy Momentum

Shares of ASP Isotopes are trading higher after the company announced a financing agreement with nuclear technology firm TerraPower.

<a href="https://www.bloomberg.com/news/articles/2025-05-23/mcdonald-s-to-close-beverage-focused-concept-test-new-drinks?srnd=homepage-asia">https://www.bloomberg.com/news/articles/2025-05-23/mcdonald-s-to-close-beverage-focused-concept-test-new-drinks?srnd=homepage-asia</a>

'McDonald's to Close Beverage-Focused Concept Stores, Test New Drinks'- Bloomberg

Press Releases

Elanco to Participate in Upcoming Investor Conferences

Elanco Enters Agreement with Medgene to Commercialize Highly Pathogenic Avian Influenza Vaccine in Dairy Cattle

Earnings

Elanco Animal Health Reports Fourth Quarter and Full Year 2024 Results

Elanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets

Elanco Confirms Date and Conference Call for First Quarter 2025 Financial Results Announcement

Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day

Legal

ELANCO ALERT: Bragar Eagel & Squire, P.C. is Investigating Elanco Animal Health Incorporated on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

Elanco Animal Health Reports First Quarter 2025 Results

Elanco to Participate in the Upcoming Investor Conferences

ELAN

TARS

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

BGM Group

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Elanco Animal Health

ニュース

パートナーシップ

ベンジンガ・グローバル